1. Home
  2. TVTX vs BMA Comparison

TVTX vs BMA Comparison

Compare TVTX & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$51.58

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Logo Banco Macro S.A.  ADR (representing Ten Class B)

BMA

Banco Macro S.A. ADR (representing Ten Class B)

SELL

Current Price

$65.09

Market Cap

5.9B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
TVTX
BMA
Founded
N/A
1966
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.9B
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
TVTX
BMA
Price
$51.58
$65.09
Analyst Decision
Strong Buy
Buy
Analyst Count
15
9
Target Price
$75.21
★ $105.90
AVG Volume (30 Days)
★ 1.6M
277.5K
Earning Date
10-29-2026
11-25-2026
Dividend Yield
N/A
★ 6.11%
EPS Growth
★ 92.89
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$47.65
$55.43
Revenue Next Year
$49.39
$9.25
P/E Ratio
★ N/A
$33.22
Revenue Growth
N/A
N/A
52 Week Low
$22.59
$51.35
52 Week High
$68.73
$106.15

Technical Indicators

Market Signals
Indicator
TVTX
BMA
Relative Strength Index (RSI) 29.63 35.32
Support Level $41.75 $63.89
Resistance Level $59.93 $69.69
Average True Range (ATR) 2.20 2.34
MACD -0.38 0.19
Stochastic Oscillator 1.49 35.89

Price Performance

Historical Comparison
TVTX
BMA

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.

Share on Social Networks: